About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

American Oncology Network Expands Access to Advanced Radioligand Therapies Across U.S. Network

By: via GlobeNewswire

FORT MYERS, Fla., May 21, 2025 (GLOBE NEWSWIRE) -- American Oncology Network (AON), one of the nation’s fastest-growing community oncology networks, today announced it is expanding access to cutting-edge radioligand therapies (RLT), providing more patients with targeted treatment options for certain metastatic and rare cancers. To date, more than 300 treatments have been delivered to nearly 70 patients across five AON partner practices, demonstrating both the growing demand for and success of these advanced therapies.

13435_AON_Guy-Messer_Press-Release_Headshot_250516 (1)

Radioligand therapies are now offered at the following AON practices:

These practices offer three FDA-approved radiopharmaceuticals:

  • Pluvicto™ – for treatment of metastatic castration-resistant prostate cancer (mCRPC)
  • Lutathera® – for adults with gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
  • Xofigo® (radium-223 dichloride) – for symptomatic mCRPC with bone metastases

“Radioligand therapy allows us to deliver highly targeted radiation directly to cancer cells, minimizing damage to healthy tissue and improving patient outcomes,” said Guy Messer, AON vice president of radiation and radiology services. “Our expansion of these therapies reflects AON’s continued commitment to ensuring that patients in community settings can access leading-edge treatments without having to travel far from home.”

Radioligand therapy, also know as radiopharmaceutical therapy, involves attaching a radioactive isotope to a targeting molecule that is injected into the bloodstream. This molecule binds to specific receptors on tumor cells, delivering a precise dose of radiation that damages or kills cancerous cells while sparing surrounding tissue.

Pluvicto™ is the first targeted radioligand therapy approved by the FDA to treat prostate-specific membrane antigen (PSMA)-positive mCRPC. Xofigo® is approved for men with mCRPC that has spread to the bone and who have already received androgen deprivation therapy. Lutathera® remains the only approved radiopharmaceutical for treating adult patients with GEP-NETs—a rare but increasingly diagnosed type of cancer that can develop in the pancreas, stomach, intestines or appendix.

“Continuing to increase the availability of these advanced radiopharmaceutical therapies in community oncology practices across the nation is a major step forward in personalized cancer care,” said Dr. Stephen “Fred” Divers, AON chief medical officer. “It’s part of AON’s broader mission to ensure patients nationwide have access to the latest innovations in oncology, without sacrificing the personalized care they receive close to home.”

AON expects continued growth in radioligand therapy utilization as additional sites gain the infrastructure and regulatory clearances needed to administer these specialized treatments.

About American Oncology Network
American Oncology Network (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success and viability of community oncology and other specialties. Founded in 2018, AON’s rapidly expanding network represents more than 290 providers practicing across 21 states. AON pioneers innovative healthcare solutions through its physician-led model, fostering value-based care that improves patient outcomes while reducing costs and expanding access to quality care. AON equips its network physicians with the tools they need to thrive independently while providing comprehensive support, integrated revenue-diversifying ancillary services, and practice management expertise, enabling physicians to focus on what matters most – providing the highest standard of care for every patient. AON is committed to promoting health equity by addressing disparities in cancer care and ensuring that all patients have access to the care they need to achieve optimal health outcomes. With a focus on innovation and collaboration, AON is shaping the future of community oncology. For more information, please visit AONcology.com or follow us on LinkedIn, Facebook, X (formerly Twitter) and YouTube.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/31ddea12-d6f2-4bf7-8cda-efb9e90eb230


Media Contact:
Karen Riley Sawyer
American Oncology Network
Karen.Sawyer@AONcology.com

Primary Logo

More News

View More
FICO’s Big Dip Could Be the Best Buying Chance of the Year
Via MarketBeat
Tickers EFX FICO
D-Wave: Reevaluating the Short Seller’s Case After the Downgrade
Via MarketBeat
Tickers QBTS RGTI
Datavault: A Speculative AI Play, But Beware of Volatility
Via MarketBeat
Topics Artificial Intelligence
Tickers DVLT IBM SCLX
Traders Are Piling Into Suncor Call Options—Should You?
Via MarketBeat
Topics World Trade
Tickers SU
Delta Air Lines Stock Looks Ready to Fly to New Highs
Via MarketBeat
Tickers DAL
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.